Peri-operative darolutamide + surgery.

Phase 2

BAYER (BAYRY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

7 competitors in Prostate Cancer

CADLaglatimagene besadenovec

Phase 3

CASIPanzem® NCD

Phase 2

SNYCabazitaxel XRP6258

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT05826509

Last updated: 8/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Oxybutynin (Oxytrol, BAY839380)Phase 3

Overactive Bladder

Amikacin Inhalation Solution (BAY41-6551)Phase 3

Pneumonia, Bacterial

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

Regorafenib (Stivarga, BAY73- 4506)Phase 3

Colorectal Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts